eMedicine Specialties > Urology > Dermatological Disorders
Dermatologic Diseases of the Male Genitalia, Malignant
Updated: Nov 2, 2009
Introduction
Most malignant cutaneous neoplasms that involve the male genitalia are squamous in origin and associated with human papillomaviruses (HPVs). The overall prevalence of HPV DNA in penile carcinoma is approximately 40-45%. Less commonly, tumors arise from cutaneous adnexa, melanocytes, soft tissue, or lymphoid tissue. Cutaneous metastases of the penis are rare and are usually associated with widely disseminated metastatic disease.
Penile neoplasia of squamous origin includes both in situ and invasive carcinoma. In situ squamous cell carcinoma of the penis, also known as penile intraepithelial neoplasia (PIN), encompasses 3 clinical variants: erythroplasia of Queyrat, Bowen disease, and bowenoid papulosis. The distinction depends on the anatomic location and clinical presentation of the lesions. Erythroplasia of Queyrat and Bowen disease share histopathologic features and biologic behavior and are associated with similar HPV subtypes. The two diseases are considered to represent clinical variants of a single pathologic process.
The in situ carcinoma microscopic features of bowenoid papulosis are also similar, and the condition is also associated with HPV; however, it differs from erythroplasia of Queyrat and Bowen disease in clinical presentation and exhibits a significantly lower rate of malignant transformation.
Invasive squamous cell carcinoma is an uncommon tumor that usually develops in older uncircumcised men. It is associated with significant morbidity and mortality, as well as psychological trauma. The etiology of invasive squamous cell carcinoma of the penis is less understood than in situ carcinoma. Although invasive squamous cell carcinoma is associated with HPV, other factors also appear to play a role in the pathogenesis of the tumors. The clinical presentation of invasive squamous cell carcinoma of the penis varies. Invasive squamous cell carcinomas of the penis are most commonly well-differentiated neoplasms that can present clinically as exophytic, verrucous, or flat lesions. The overall prognosis of penile squamous cell carcinoma is related to the extent of tumor invasion and regional lymph node status.
Nonsquamous malignant neoplasms of the penis are rare and include soft tissue sarcomas, melanomas, and lymphomas.
For excellent patient education resources, visit eMedicine's Men's Health Center and Cancer and Tumors Center. Also, see eMedicine's patient education article Cancer: What You Need to Know.
Erythroplasia of Queyrat
Introduction
Initially described by Tarnowsky in 1891, erythroplasia of Queyrat (see Erythroplasia of Queyrat [Bowen Disease of the Glans Penis]) was separated from Bowen disease based on clinical appearance, anatomic location (inner lining of the foreskin and glans penis), and lack of an association with internal malignancy. The histopathologic features and rates of progression to squamous cell carcinoma are similar for both erythroplasia of Queyrat and Bowen disease. Because of the clinical and biologic overlap of the two diseases, they are thought to represent clinical variants of in situ squamous cell carcinoma of the penis. The reported association with internal malignancy may be more related to the older age of the patients and has been called into question for both erythroplasia of Queyrat and Bowen disease.
Pathophysiology
Erythroplasia of Queyrat generally develops in elderly uncircumcised men. The lesion is an intraepithelial or in situ neoplasm; the associated risk for progression to invasive carcinoma has been documented as up to 10%. The specific etiologic factors remain unclear. Predisposing factors include lack of circumcision, poor hygiene, and chronic infection. Several HPV serotypes have been isolated from this disease, including HPV 8, 16, 18, 39, and 51. Circumcision has been proposed to protect against the development of erythroplasia of Queyrat, possibly secondary to facilitation of better hygiene, less accumulation of smegma, and reduced risk of chronic infections.
Clinical presentation/diagnosis
Erythroplasia of Queyrat presents as a bright red, well-demarcated, velvety plaque or plaques that involve the glans, coronal sulcus, or prepuce. Lesions are often present for months to years before clinical attention is sought. Biopsy is necessary for a definitive diagnosis. Ulceration may signal an invasive lesion. The histopathology is similar to that of bowenoid papulosis and Bowen disease, showing features of in situ carcinoma such as full-thickness epithelial atypia with lack of maturation, nuclear atypia, dyskeratosis, and atypical mitoses. The underlying dermis typically displays a lymphohistiocytic inflammatory infiltrate. Evidence of tumor invasion into the underlying dermis is absent.
Erythroplasia of Queyrat (Image courtesy of Hon Pak, MD)
Differential diagnoses
Differential diagnoses include Zoon balanitis (see Balanitis Circumscripta Plasmacellularis), erosive lichen planus (see Cicatricial Pemphigoid), psoriasis (see Candidiasis, Cutaneous), fixed drug eruption (see Psoriasis), and lichen planus (see Lichen Planus). Pigmented Bowen disease can also mimic seborrheic keratosis, melanoma (see Malignant Melanoma), or melanocytic nevi (see Melanocytic Nevi).
Treatment
Treatment of erythroplasia of Queyrat involves removal or destruction of the lesion; however, no therapy is standard. Treatment methods used include topical therapy, cryotherapy, laser ablation, radiotherapy, diathermy, surgical excision (including partial penectomy), and Mohs micrographic surgery. The latter 2 surgical modalities have the advantage of allowing microscopic examination of the specimen to assess clear margins and ruling out the presence of invasive tumor. Mohs micrographic surgery offers the additional advantage of maximizing tissue preservation. More recently, photodynamic therapy in conjunction with Mohs micrographic surgery has been used. Topical therapy with either 5-fluorouracil (5-FU) or imiquimod has shown success in limited studies.
Outcome
Approximately 10% of lesions show progression to invasive squamous cell carcinoma. In a series of 100 cases, 22% of the patients developed recurrence, 8% developed invasive squamous cell carcinoma, and 2% developed squamous cell carcinoma with distant metastases.
Bowen Disease
Introduction
Described by Bowen in 1912, this disease (see Bowen Disease) was considered unique because of its association with invasive squamous cell carcinoma and internal visceral malignancy. Subsequently, the rate of progression to invasive carcinoma was shown to be similar to that of erythroplasia of Queyrat. A significant association with internal malignancy has not been demonstrated.
Pathophysiology
Bowen disease is a clinical presentation of in situ squamous cell carcinoma that involves the shaft of the penis. The pathogenesis is unclear; however, risk factors include exposure to ultraviolet light, chemical carcinogens, and arsenic. HPV types 16, 18, and 57b have been isolated from lesions of Bowen disease. However, the specific role of HPV in the pathogenesis is debated.
Clinical presentation/diagnosis
Bowen disease is generally seen in elderly uncircumcised men and presents as a sharply marginated, erythematous, scaly patch or plaque on the shaft of the penis. A pigmented variant exists. The lesion can range from millimeters to centimeters in diameter. Ulceration may signal an invasive lesion. Biopsy is necessary for a definitive diagnosis. The histopathology is similar to that of bowenoid papulosis and erythroplasia of Queyrat, showing features of in situ carcinoma, such as full-thickness epithelial atypia with lack of maturation, nuclear atypia, dyskeratosis, and atypical mitoses. The underlying dermis typically displays a lymphohistiocytic inflammatory infiltrate. Evidence of tumor invasion into the underlying dermis is absent.
Differential diagnoses
Differential diagnoses include Paget disease, squamous cell carcinoma (see Squamous Cell Carcinoma), psoriasis (see Psoriasis), and lichen planus (see Lichen Planus). Pigmented Bowen disease can also mimic seborrheic keratosis, melanoma (see Malignant Melanoma), or melanocytic nevi (see Melanocytic Nevi).
Treatment
Treatment of Bowen disease involves removal or destruction of the lesion; however, no therapy is standard. Treatment methods include topical therapy, cryotherapy, laser ablation, surgical excision, and Mohs micrographic surgery. The latter two surgical modalities have the advantage of allowing microscopic examination of the specimen to assess clear margins and to rule out the presence of invasive tumor. Mohs micrographic surgery offers the additional advantage of maximizing tissue preservation. Topical therapy with either 5-FU or imiquimod has shown success in limited studies.
Outcome
The rate of progression to invasive squamous cell carcinoma is 5-10%, similar to that observed in erythroplasia of Queyrat. Of the cases progressing to invasive carcinoma, 30-50% are potentially metastatic. Initial reports suggested that as many as 33% of patients with Bowen disease develop visceral malignancies including respiratory, gastrointestinal, or urogenital cancers. Subsequent studies have not demonstrated a paraneoplastic association.
Bowenoid Papulosis
Introduction
In 1970, Lloyd first described lesions of bowenoid papulosis.1 Wade initially applied the term bowenoid papulosis in 1978 (see Bowenoid Papulosis) as a specific disorder seen predominantly in young, sexually active males.2 Although the lesions show histopathologic features of in situ carcinoma similar to those of erythroplasia of Queyrat and Bowen disease, they exhibit a much lower rate of progression to invasive neoplasms.
Pathophysiology
Bowenoid papulosis generally develops in sexually active men aged 20-40 years. The mean age at presentation is 29.5 years. An association with HPV infection has been documented, and several HPV serotypes from lesions of bowenoid papulosis have been detected, including HPV 1, 6, 11, 16, 18, 31-35, 39, 42, 48, 51-54, and 67. HPV 16 is the most commonly detected serotype. Although bowenoid papulosis can show progression to squamous cell carcinoma, the rate (2.6%) is significantly less than that of erythroplasia of Queyrat or Bowen disease.
Clinical presentation/diagnosis
Patients typically present with solitary or multiple, rapidly growing, red-brown to violaceous, flat-topped papules that may coalesce into larger plaques on the penile shaft or the perineum. The papules are nonpruritic, range in size from 2-10 mm, and usually lack scale. Biopsy is usually necessary for a definitive diagnosis. The histopathology is similar to that of erythroplasia of Queyrat and Bowen disease, showing features of in situ carcinoma, including full-thickness epithelial atypia with lack of maturation, nuclear atypia, dyskeratosis, and atypical mitoses. The underlying dermis typically displays a lymphohistiocytic inflammatory infiltrate. Evidence of tumor invasion into the underlying dermis is absent. Because of the histopathologic overlap with erythroplasia of Queyrat and Bowen disease, correlation with the clinical presentation is essential for diagnosis.
Differential diagnoses
Lesions may be clinically mistaken for condyloma acuminatum (see Condyloma Acuminatum), seborrheic keratoses (see Seborrheic Keratoses), or nevi. Differential diagnoses also include nonspecific balanitis, including Zoon balanitis (see Balanitis Circumscripta Plasmacellularis).
Treatment
Because of the characteristic benign course of the disease, conservative therapy is appropriate. Treatment centers on ablation of the gross lesion or lesions. Modalities include cryotherapy, laser ablation, and topical therapy with either 5-FU or imiquimod. Remission has been demonstrated in patients infected with HIV who are receiving highly active antiretroviral therapy (HAART).
Outcome
The risk of progression from bowenoid papulosis to squamous cell carcinoma, reported as 2.6%, is significantly less than Bowen disease and erythroplasia of Queyrat. Immunosuppressed patients are at greater risk of developing invasive lesions. In some cases, bowenoid papulosis may regress spontaneously. Because of the association with HPV, this is considered a sexually transmitted disease. Studies of partners of patients with bowenoid papulosis found them to be at a higher risk for cervical dysplasia.
Squamous Cell Carcinoma
Introduction
Squamous cell carcinoma (see Squamous Cell Carcinoma) is the most common malignant tumor of the penis, accounting for more than 95% of all malignant penile neoplasms. Although rare in persons younger than 40 years, the age at presentation ranges from 20-90 years. Most cases occur in elderly uncircumcised men and are associated with poor hygiene. In the United States, penile cancer accounts for less than 1% of all malignancies. Areas of high rates of penile squamous cell carcinoma include Uganda, Brazil, Jamaica, Mexico, India, and Haiti. Squamous cell carcinoma of the scrotum also occurs but is less common than squamous cell carcinoma of the penis.
Pathophysiology
The specific etiology and pathogenesis of penile squamous cell carcinoma is unclear. Initial reports showed that penile squamous cell carcinoma was associated with lack of circumcision. High rates of tumors were documented in uncircumcised Hindus and low rates among Jews who practice ritual circumcision. Later studies revealed a low rate of penile tumors among Scandinavians who do not practice circumcision and indicated that the crucial factor was not the foreskin itself, but the link between foreskin retention and poor hygiene.
Squamous cell carcinoma of the penis has been associated with phimosis; however, the presence of phimosis often indicates scarring from a previous infectious or inflammatory reaction. HPV infection is associated with 15-71% of penile squamous cell carcinomas. Subtypes linked to penile squamous cell carcinoma include high-risk types 16 and 18, as well as 6, 11, and 30. Penile cancer is also associated with spousal cervical cancer, although these statistics have been debated. Additional suggested risk factors associated with the development of penile carcinoma include smegma retention, chronic balanitis, ultraviolet light exposure, chemical carcinogen exposure, cigarette smoking, HIV infection, and immunosuppression.
Clinical presentation/diagnosis
Most lesions present on the glans, followed by the prepuce, coronal sulcus, and shaft. Tumors typically present as an ulcerated mass and can exhibit either a flat or an exophytic, papillary clinical growth pattern. Presenting symptoms often include penile pain, malignant priapism, discharge, and difficulty voiding. Lymphadenopathy is present in 28-64% of cases at presentation. Biopsy is necessary for a definitive diagnosis. The histopathology shows features of invasive carcinoma and can exhibit morphologic heterogeneity. Most tumors are well-differentiated squamous cell carcinomas. Other variants include basaloid, sarcomatoid (or spindled), and verrucous growth patterns. The underlying dermis typically displays a lymphohistiocytic inflammatory infiltrate. Angiolymphatic invasion may be present.
Patients are staged and tumors are graded according to the American Joint Committee on Cancer (AJCC) tumor, node, and metastasis (TNM) staging and modified Broders systems, respectively. The TNM system classifies cases into stages I-IV based on the extension of the tumor. Most patients present as stage I (confined to the glans) or II (involving the glans and invading into the penile shaft). Histologic grading using the modified Broders classification divides tumors into 4 histologic grades ranging from well differentiated to poorly differentiated. Another grading system uses a 3-tier (well, moderate, poor) scale for differentiation, with 50% of cases being well differentiated. Of note, well-differentiated tumors metastasize to regional lymph nodes at a rate of 50%, while moderate or poorly differentiated tumors have an 80-100% nodal metastasis rate. Hematogenous metastasis is uncommon, accounting for fewer than 2% of cases at diagnosis.
Squamous cell carcinoma of the penis: This lesion is large but mainly shows broad superficial invasion upon sectioning. The white jagged line is the fibrotic response to the invading tumor.
Squamous cell carcinoma of the penis: This case obliterates the tip of the glans and distorts the prepuce. Note the large size, typical of these lesions at presentation.
Squamous cell carcinoma of the prepuce: The ulcerating tumor is noted to arise from a background of inflamed prepuce.
Squamous cell carcinoma (Image courtesy of Hon Pak, MD)
Squamous cell carcinoma (Image courtesy of Hon Pak, MD)
Differential diagnoses
Given the anatomic location and clinical presentation, the diagnosis of squamous cell carcinoma is generally straightforward. The differential diagnoses include HPV infection, atypical herpes simplex infection, malignant cutaneous adnexal tumors, sarcomas, and amelanotic melanoma.
Treatment
The primary treatment for penile carcinoma is surgical and varies according to tumor type and stage of disease. Radiation, chemotherapy, or both are often used as adjunctive therapy, depending on the stage of disease. Surgical intervention involves wide excision, partial penectomy, or total penectomy. Some groups have argued for local excision with conversion to partial penectomy upon recurrence, although this is not widely accepted. The effectiveness of prophylactic bilateral inguinal node dissection is controversial. Sentinel lymph node biopsy has been successfully used in the surgical management of penile carcinoma and can provide staging and prognostic information.
Radiation therapy has been used in patients who are not surgical candidates, with limited success. The role of chemotherapy is unclear because of the difficulty in gathering a sizable number of patients. Commonly used agents include cisplatin and bleomycin and have yielded response rates of 15-23%. Combination chemotherapy and radiation using bleomycin-derived treatments have been successful in some cases, with response rates as high as 43%.
Outcome
Squamous cell carcinoma of the penis tends to be a locally advanced, aggressive disease. The prognosis correlates with the extent of tumor invasion and lymph nodes status. Survival is most closely related to lymph node status. According to a recent study, the 5-year survival rate is 93% for stage I, 55% for stage II, and 30% for stage III disease. Involvement of the pelvic lymph nodes is associated with a 5-year survival rate of less than 5%. Death typically occurs within 2 years if tumors are left untreated. Nodal metastases, usually to the inguinal and/or iliac nodes, are the most common route of dissemination. Of note, 5-15% develop second primary lesions, often located in the residua of the penis.
Complications are usually due to recurrence, which occurs in as many as 7% of patients. In addition to the extent of tumor invasion and lymph node status, histologic type plays a role in prognosis. Worse prognosis is associated with basaloid and sarcomatoid subtypes. Verrucous carcinoma (Buschke-Lowenstein tumor) is a well-differentiated, low-grade variant of squamous cell carcinoma characterized by local invasion and a low incidence of metastasis.
Basal Cell Carcinoma
Introduction
While basal cell carcinomas (see Basal Cell Carcinoma) are the most common human malignant tumor, they are distinctly uncommon on the male genitalia. Most cases documented in medical literature have been case reports or letters. Treatment is directed at local control. Metastases are extremely rare.
Pathophysiology
Basal cell carcinoma typically develops on sun-exposed skin and is most closely associated with ultraviolet radiation exposure. Given the paucity of ultraviolet radiation exposure in the male genitalia, the tumors are uncommon at this site. In addition to sun exposure, risk factors for basal cell carcinoma include ionizing radiation, arsenic ingestion, immunosuppression, and inherited syndromes such as nevoid basal cell carcinoma syndrome and xeroderma pigmentosum. The tumors are locally destructive but rarely metastasize.
Clinical presentation/diagnosis
The age at presentation ranges from 22-81 years, with most cases in older men. Most patients have fair skin, although cases in persons of color have also been reported. Most lesions have occurred on the shaft and scrotum and were present for years before the patient sought treatment. The lesion is papular or nodular, with pearly white borders and telangiectatic edges. Ulceration may be present. Biopsy is necessary for a definitive diagnosis. The histopathology shows nests of basaloid cells with peripheral palisading, focal mucin, and areas of retraction artifact form the adjacent connective tissue stroma.
Nodular basal cell carcinoma (Image courtesy of Hon Pak, MD)
Differential diagnoses
Primary squamous cell carcinomas (see Squamous Cell Carcinoma) must be excluded based on microscopic examination because of their more aggressive clinical course and potential for metastasis. Additional differential diagnoses include primary cutaneous adnexal carcinoma, such as eccrine porocarcinoma (see Eccrine Carcinoma). Malignant adnexal tumors tend to have a more aggressive microscopic growth pattern and higher rate of metastasis and require more aggressive treatment. From a histopathological perspective, the basaloid variant of squamous cell carcinoma must be distinguished from basal cell carcinoma. Basaloid squamous cell carcinoma typically arises on the glans penis and exhibits much greater cytologic atypia. Definitive diagnosis is based on histopathologic examination.
Treatment
Treatment for basal cell carcinoma focuses on local excision or ablation. Mohs micrographic surgery has also been successful. Topical therapy with imiquimod and 5-FU has shown success in limited studies. The treatment for basal cell carcinoma is in contrast to the more radical therapy used in the treatment of penile squamous cell carcinoma.
Outcome
For small lesions, complete excision of the tumor is generally curative. Incomplete treatment often results in local recurrence. Larger, more deeply infiltrative lesions can show significant local destruction, but metastasis is extremely rare.
Melanoma
Introduction
Melanoma (see Malignant Melanoma) is an uncommon neoplasm of the male genitalia. Primary tumor sites include the penis, scrotum, and urethra. Melanoma accounts for less than 2% of primary malignant tumors of the penis. Scrotal and urethral tumors are less frequent. Patients with melanoma of the male genitalia generally have a poor prognosis due to presentation at an advanced stage.
Pathophysiology
Melanoma originates from epidermal or mucosal melanocytes. In a minority of cases, lesions are associated with a melanocytic nevus. Most patients present with advanced disease. Inguinal node metastases are common (43-62% of cases at presentation).
Clinical presentation/diagnosis
Men aged 50-70 years are generally affected. One series documented an age range of 57-77 years. On the penis, the most common tumor site is the glans (55% in one series); however, melanoma has been described on both the prepuce (28%) and shaft (9%). The lesions are typically asymmetric macules with irregular borders and variable pigmentation. Clinically evident inguinal lymph node enlargement is seen in a minority of patients. Biopsy is necessary for definitive diagnosis. The histopathologic features are similar to melanomas at other sites. Patients are staged according to the current (2001) AJCC melanoma staging system.
Malignant melanoma (Image courtesy of Hon Pak, MD)
Differential diagnoses
Differential diagnoses include melanoma in situ, melanocytic nevi, seborrheic keratosis, lentigines, and melanosis.
Treatment
Surgical excision is the primary treatment for melanoma of the male genitalia. Partial penectomy with or without inguinal lymph node dissection is the most common surgical therapy for penile and urethral tumors. Wide local excision is used to treat scrotal tumors. Sentinel lymph node biopsy is performed in some cases.
Outcome
As with melanoma at other sites, prognosis correlates with depth of tumor invasion and regional lymph node status. Because of the advanced stage at presentation, the prognosis for men with genital melanoma is poor, regardless of treatment. In one series, 7 of 9 patients (2 with lymph node metastases) died of disease within 3 years of presentation. Although most patients present with advanced stage disease, long-term survival has been demonstrated in patients with thin tumors who have no evidence of lymph node metastasis.
Kaposi Sarcoma
Introduction
Although Kaposi sarcoma (see Kaposi Sarcoma) was once a rare neoplasm of the lower extremities in older men of Mediterranean descent, the incidence of the disease has increased 7000-fold in the HIV/AIDS era. Lesions of Kaposi sarcoma are very common in individuals infected with HIV and are often the presenting sign or symptom of HIV/AIDS. However, Kaposi sarcoma has become uncommon in patients infected with HIV who are treated with HAART.
Pathophysiology
The specific histogenesis of Kaposi sarcoma has been controversial, but it now appears to be a vascular tumor of endothelial origin. Association f this vascular tumor with human herpesvirus 8 (HHV-8, Kaposi sarcoma–associated herpesvirus) infection has been documented in HIV and non-HIV forms of disease.
Clinical presentation/diagnosis
Kaposi sarcoma has been classified into 4 clinical groups, as follows:
- Classic (endemic) form occurring in elderly males of Mediterranean descent
- African Kaposi sarcoma
- AIDS-related Kaposi sarcoma
- Immunosuppression-related Kaposi sarcoma.
While the classic type was rarely seen in the genital area, approximately 20% of HIV-seropositive men with Kaposi sarcoma have genital involvement, and 3% of these patients present with genital involvement. Kaposi sarcoma presents as small violaceous-to-tan patches or nodules that may eventually coalesce to form plaques. Occasionally, lesions become exophytic or superficially ulcerated. Complications of genital involvement include lymphatic or urethral obstruction. Skin biopsy is generally necessary for definitive diagnosis. Histopathology shows an atypical spindle-cell vascular proliferation with slitlike vascular channels and numerous extravasated erythrocytes.
Differential diagnoses
The clinical differential diagnoses of Kaposi sarcoma include hemangioma, angiosarcoma, pyogenic granuloma, squamous cell carcinoma, amelanotic melanoma, dermatofibroma, and bacillary angiomatosis.
Treatment
Although no cure has been identified, care is centered on limiting potential complications (obstruction) or cosmetic treatment. Topical alitretinoin, intralesional chemotherapeutics, radiation therapy, and local tissue destruction with cryotherapy or laser therapy have been used with varying success. Optimizing the HIV antiviral regimen generally results in involution of Kaposi sarcoma in individuals infected with HIV. Systemic chemotherapy with liposomal doxorubicin is frequently effective for patients with widespread disease or debilitating lesions.
Outcome
Although no cure is currently known, the use of multidrug antiviral regimens to treat patients infected with HIV can effectively induce involution of Kaposi sarcoma lesions.
Multimedia
 | Media file 1: Squamous cell carcinoma of the penis: This lesion is large but mainly shows broad superficial invasion upon sectioning. The white jagged line is the fibrotic response to the invading tumor. |
 | Media file 2: Squamous cell carcinoma of the penis: This case obliterates the tip of the glans and distorts the prepuce. Note the large size, typical of these lesions at presentation. |
 | Media file 3: Squamous cell carcinoma of the prepuce: The ulcerating tumor is noted to arise from a background of inflamed prepuce. |
 | Media file 4: Nodular basal cell carcinoma (Image courtesy of Hon Pak, MD) |
 | Media file 5: Erythroplasia of Queyrat (Image courtesy of Hon Pak, MD) |
 | Media file 6: Malignant melanoma (Image courtesy of Hon Pak, MD) |
 | Media file 7: Squamous cell carcinoma (Image courtesy of Hon Pak, MD) |
 | Media file 8: Squamous cell carcinoma (Image courtesy of Hon Pak, MD) |
Keywords
erythroplasia of Queyrat, Bowen disease, Bowen's disease, bowenoid papulosis, squamous cell carcinoma, basal cell carcinoma, melanoma, Kaposi sarcoma, Kaposi's sarcoma
More on Dermatologic Diseases of the Male Genitalia, Malignant |
| References |
References
Lloyd KM. Multicentric pigmented Bowen's disease of the groin. Arch Dermatol. Jan 1970;101(1):48-51. [Medline].
Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the penis. Cancer. Oct 1978;42(4):1890-903. [Medline].
Penis. In: Greene FL, Page DL, Fleming ID, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: 2002:303-8.
Angulo JC, Lopez JI, Unda-Urzaiz M, Larrinaga JR, Zubiaur CL, Flores NC. Kaposi's sarcoma of the penis as an initial urological manifestation of AIDS. A report of two cases. Urol Int. 1991;46(2):235-7. [Medline].
Antonini C, Zucconelli R, Forgiarini O. Carcinosarcoma of penis. Case report and review of the literature. Adv Clin Path. Oct 1997;1(4):281-5. [Medline].
Arlette JP. Treatment of Bowen's disease and erythroplasia of Queyrat. Br J Dermatol. Nov 2003;149 Suppl 66:43-9. [Medline].
Avrach WW, Christensen HE. Metastasizing erythroplasia Queyrat. Report of a case. Acta Derm Venereol. 1976;56(5):409-12. [Medline].
Balch CM, Buzaid AC, Soong SJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. Aug 15 2001;19(16):3635-48. [Medline].
Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. Apr 2009;27(2):141-50. [Medline].
Brown MD, Zachary CB, Grekin RC. Genital tumors: their management by micrographic surgery. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):115-22. [Medline].
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. Dec 16 1994;266(5192):1865-9. [Medline].
Chang YT, Liu HN, Wong CK. Penile basal cell carcinoma with eccrine differentiation. Clin Exp Dermatol. Nov 1995;20(6):487-9. [Medline].
Chen MF, Chen WC, Wu CT, Chuang CK, Ng KF, Chang JT. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol. Apr 2004;22(1):60-6. [Medline].
Chun YS, Chang SN, Park WH. A case of classical Kaposi's sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol. Apr 1999;26(4):240-3. [Medline].
Collina G, Rossi E, Bettelli S, Cook MG, Cesinaro AM, Trentini GP. Detection of human papillomavirus in extragenital Bowen's disease using in situ hybridization and polymerase chain reaction. Am J Dermatopathol. Jun 1995;17(3):236-41. [Medline].
Connell CF, Berger NA. Management of advanced squamous cell carcinoma of the penis. Urol Clin North Am. Nov 1994;21(4):745-56. [Medline].
Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol. Apr 2009;27(2):189-96. [Medline].
Cubilla AL. Carcinoma of the penis. Mod Pathol. Jan 1995;8(1):116-8. [Medline].
Cubilla AL, Barreto J, Caballero C, Ayala G, Riveros M. Pathologic features of epidermoid carcinoma of the penis. A prospective study of 66 cases. Am J Surg Pathol. Aug 1993;17(8):753-63. [Medline].
Cubilla AL, Reuter V, Velazquez E. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol. Apr 2001;9(2):111-20. [Medline].
Cubilla AL, Velazques EF, Reuter VE, Oliva E, Mihm MC Jr, Young RH. Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of 'verruciform' penile tumors. Am J Surg Pathol. Apr 2000;24(4):505-12. [Medline].
Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol. Aug 2003;170(2 Pt 1):359-65. [Medline].
Cuozzo DW, Vachher P, Sau P. Verruciform xanthoma: a benign penile growth. J Urol. May 1995;153(5):1625-7. [Medline].
Cupp MR, Malek RS, Goellner JR. The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol. Sep 1995;154(3):1024-9. [Medline].
Davis JW, Schellhammer PF, Schlossberg SM. Conservative surgical therapy for penile and urethral carcinoma. Urology. Feb 1999;53(2):386-92. [Medline].
de Bree E, Sanidas E, Tzardi M. Malignant melanoma of the penis. Eur J Surg Oncol. Jun 1997;23(3):277-9. [Medline].
Demitsu T, Nagato H, Nishimaki K. Melanoma in situ of the penis. J Am Acad Dermatol. Feb 2000;42(2 Pt 2):386-8. [Medline].
Demkow T. The treatment of penile carcinoma: experience in 64 cases. Int Urol Nephrol. 1999;31(4):525-31. [Medline].
Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol. Dec 2000;136(12):1461-9. [Medline].
Gerbaulet A, Lambin P. Radiation therapy of cancer of the penis. Indications, advantages, and pitfalls. Urol Clin North Am. May 1992;19(2):325-32. [Medline].
Gerber GS. Carcinoma in situ of the penis. J Urol. Apr 1994;151(4):829-33. [Medline].
Goldminz D, Scott G, Klaus S. Penile basal cell carcinoma. Report of a case and review of the literature. J Am Acad Dermatol. Jun 1989;20(6):1094-7. [Medline].
Greenbaum SS, Glogau R, Stegman SJ. Carbon dioxide laser treatment of erythroplasia of Queyrat. J Dermatol Surg Oncol. Jul 1989;15(7):747-50. [Medline].
Greenbaum SS, Krull EA, Simmons EB. Basal cell carcinoma at the base of the penis in a black patient. J Am Acad Dermatol. Feb 1989;20(2 Pt 2):317-9. [Medline].
Gregoire L, Cubilla AL, Reuter VE. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst. Nov 15 1995;87(22):1705-9. [Medline].
Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl). Feb 2004;193(1):35-44. [Medline].
Grunwald MH, Amichai B, Halevy S. Purplish penile papule as a presenting sign of Kaposi's sarcoma. Br J Urol. Oct 1994;74(4):517. [Medline].
Han KR, Brogle BN, Goydos J. Lymphatic mapping and intraoperative lymphoscintigraphy for identifying the sentinel node in penile tumors. Urology. Apr 2000;55(4):582-5. [Medline].
Happle R. Surgical treatment of erythroplasia of Queyrat. Plast Reconstr Surg. May 1977;59(5):642-5. [Medline].
Harish K, Ravi R. The role of tobacco in penile carcinoma. Br J Urol. Mar 1995;75(3):375-7. [Medline].
Horenblas S, van Tinteren H. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol. May 1994;151(5):1239-43. [Medline].
Inagaki H, Nonaka M, Eimoto T. Bowenoid papulosis showing polyclonal nature. Diagn Mol Pathol. Apr 1998;7(2):122-6. [Medline].
Jablonska S, Majewski S. Bowenoid papulosis transforming into squamous cell carcinoma of the genitalia [letter; comment]. Br J Dermatol. Sep 1999;141(3):576-7. [Medline].
Kaye V, Zhang G, Dehner LP, Fraley EE. Carcinoma in situ of penis. Is distinction between erythroplasia of Queyrat and Bowen's disease relevant?. Urology. Dec 1990;36(6):479-82. [Medline].
Kim ED, Kroft S, Dalton DP. Basal cell carcinoma of the penis: case report and review of the literature. J Urol. Nov 1994;152(5 Pt 1):1557-9. [Medline].
Knoll LD, Segura JW, Benson RC Jr. Bowenoid papulosis of the penis: successful management with neodymium:YAG laser. J Urol. Jun 1988;139(6):1307-9. [Medline].
Koch MO, Smith JA Jr. Local recurrence of squamous cell carcinoma of the penis. Urol Clin North Am. Nov 1994;21(4):739-43. [Medline].
Kossow AS, Cotelingam JD, MacFarland F. Bowenoid papulosis of the penis. J Urol. Jan 1981;125(1):124-6. [Medline].
Kroon BK, Horenblas S, Nieweg OE. Contemporary management of penile squamous cell carcinoma. J Surg Oncol. Jan 1 2005;89(1):43-50. [Medline].
Ladocsi LT, Siebert CF Jr, Rickert RR. Basal cell carcinoma of the penis. Cutis. Jan 1998;61(1):25-7. [Medline].
Lands RH, Ange D, Hartman DL. Radiation therapy for classic Kaposi's sarcoma presenting only on the glans penis. J Urol. Feb 1992;147(2):468-70. [Medline].
Larsson KB, Shaw HM, Thompson JF, Harman RC, McCarthy WH. Primary mucosal and glans penis melanomas: the Sydney Melanoma Unit experience. Aust N Z J Surg. Feb 1999;69(2):121-6. [Medline].
Lee MR, Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas J Dermatol. Aug 2005;46(3):196-8. [Medline].
Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection. Jun 2005;33(3):140-7. [Medline].
Lowe FC, Lattimer DG, Metroka CE. Kaposi's sarcoma of the penis in patients with acquired immunodeficiency syndrome. J Urol. Dec 1989;142(6):1475-7. [Medline].
Lubke WL, Thompson IM. The case for inguinal lymph node dissection in the treatment of T2-T4, N0 penile cancer. Semin Urol. May 1993;11(2):80-4. [Medline].
Lycka BA. Bowen's disease and internal malignancy. A meta-analysis. Int J Dermatol. Oct 1989;28(8):531-3. [Medline].
Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol. Mar 2006;54(3):369-91; quiz 391-4. [Medline].
Mikhail GR. Cancers, precancers, and pseudocancers on the male genitalia. A review of clinical appearances, histopathology, and management. J Dermatol Surg Oncol. Dec 1980;6(12):1027-35. [Medline].
Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. Apr 2004;5(4):240-7. [Medline].
Mitsuishi T, Sata T, Iwasaki T. The detection of human papillomavirus 16 DNA in erythroplasia of Queyrat invading the urethra. Br J Dermatol. Jan 1998;138(1):188-9. [Medline].
Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. Mar 2006;154(3):498-504. [Medline].
Nguyen H, Saadat P, Bennett RG. Penile basal cell carcinoma: two cases treated with Mohs micrographic surgery and remarks on pathogenesis. Dermatol Surg. Jan 2006;32(1):135-44. [Medline].
Ohnishi T, Kano R, Nakamura Y. Genital Bowen disease associated with an unusual human papillomavirus type 57b [letter]. Arch Dermatol. Jul 1999;135(7):858-9. [Medline].
Oldbring J, Mikulowski P. Malignant melanoma of the penis and maleurethra. Report of nine cases and review of the literature. Cancer. Feb 1 1987;59(3):581-7. [Medline].
Oliva E, Quinn TR, Amin MB. Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol. Jun 2000;24(6):785-96. [Medline].
Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments?. World J Urol. Apr 2009;27(2):221-5. [Medline].
Park KC, Kim KH, Youn SW. Heterogeneity of human papillomavirus DNA in a patient with Bowenoid papulosis that progressed to squamous cell carcinoma. Br J Dermatol. Dec 1998;139(6):1087-91. [Medline].
Patterson JW, Kao GF, Graham JH. Bowenoid papulosis. A clinicopathologic study with ultrastructural observations. Cancer. Feb 15 1986;57(4):823-36. [Medline].
Pettaway CA, Pisters LL, Dinney CP. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol. Dec 1995;154(6):1999-2003. [Medline].
Poblet E, Alfaro L, Fernander-Segoviano P. Human papillomavirus-associated penile squamous cell carcinoma in HIV-positive patients. Am J Surg Pathol. Sep 1999;23(9):1119-23. [Medline].
Porter WM, Francis N, Hawkins D, Dinneen M, Bunker CB. Penile intraepithelial neoplasia: clinical spectrum and treatment of 35 cases. Br J Dermatol. Dec 2002;147(6):1159-65. [Medline].
Raghavaiah NV, Soloway MS, Murphy WM. Malignant penile horn. J Urol. Dec 1977;118(6):1068-9. [Medline].
Revuz J, Clerici T. Penile melanosis. J Am Acad Dermatol. Apr 1989;20(4):567-70. [Medline].
Rosen T, Hoffman J, Jones A. Penile Kaposi's sarcoma. J Eur Acad Dermatol Venereol. Jul 1999;13(1):71-3. [Medline].
Roszkiewicz A, Roszkiewicz J, Lange M, Tukaj C. Kaposi's sarcoma following long-term immunosuppressive therapy: clinical, histologic, and ultrastructural study. Cutis. Mar 1998;61(3):137-41; quiz 152. [Medline].
Ruszczak Z, Stadler R, Schwartz RA. Kaposi's sarcoma limited to penis treated with cobalt-60 radiotherapy. J Med. 1996;27(3-4):211-20. [Medline].
Schwartz RA. Verrucous carcinoma of the skin and mucosa. J Am Acad Dermatol. Jan 1995;32(1):1-21; quiz 22-4. [Medline].
Skinner SM. Basal cell carcinoma of the penis. Cutis. Mar 1998;61(3):128B. [Medline].
Smith HR, Black MM. Basal cell carcinoma of the penis. Br J Dermatol. Feb 1999;140(2):361-2. [Medline].
Snoeck R, Van Laethem Y, De Clercq E, De Maubeuge J, Clumeck N. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch Intern Med. Oct 22 2001;161(19):2382-4. [Medline].
Sonnex TS, Ralfs IG, Plaza de Lanza M. Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery. Br J Dermatol. May 1982;106(5):581-4. [Medline].
Stillwell TJ, Zincke H, Gaffey TA. Malignant melanoma of the penis. J Urol. Jul 1988;140(1):72-5. [Medline].
Swierzewski SJ 3rd, Wan J, Boffini A, Faerber GJ. The management of meatal obstruction due to Kaposi's sarcoma of the glans penis. J Urol. Jul 1993;150(1):193-5. [Medline].
Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol. Jun 2005;173(6):1958-65. [Medline].
Tanis PJ, Lont AP, Meinhardt W. Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol. Jul 2002;168(1):76-80. [Medline].
Testori A, Mazzarol G, Viale G. Medical decision making for melanoma of the glans penis. J Exp Clin Cancer Res. Jun 1999;18(2):219-21. [Medline].
Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev. Oct-Dec 2003;5(4):222-9. [Medline].
Villavicencio H, Rubio-Briones J, Regalado R. Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur Urol. 1997;32(4):442-7. [Medline].
Wilson C, Dawber R. CO2 laser treatment of erythroplasia of Queyrat. J Dermatol Surg Oncol. May 1990;16(5):490-1. [Medline].
Further Reading
Keywords
erythroplasia of Queyrat, Bowen disease, Bowen's disease, bowenoid papulosis, squamous cell carcinoma, basal cell carcinoma, melanoma, Kaposi sarcoma, Kaposi's sarcoma
